drugset / Trial / NCT02422121
Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will investigate the effect of treatment with RNS60 for 21 days. Subjects' FEV1 will be measured after an inhaled allergen challenge at baseline and again after 21 days of treatment.
Timeline
- Start
- 2015-04
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RNS60 | Other / unclassified | 4 ml | Inhaled |